

Evi S Lianidou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6126424/publications.pdf>

Version: 2024-02-01

163
papers

8,161
citations

31902

53
h-index

53109

85
g-index

166
all docs

166
docs citations

166
times ranked

9555
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions. <i>Science of the Total Environment</i> , 2022, 804, 150151.	3.9	116
2	Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. <i>Blood Advances</i> , 2022, 6, 189-199.	2.5	10
3	The value proposition of integrative diagnostics for (early) detection of cancer. On behalf of the EFLM interdisciplinary Task and Finish Group "CNAPS/CTC for early detection of cancer". <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 821-829.	1.4	6
4	Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy. <i>Cancers</i> , 2022, 14, 1574.	1.7	8
5	Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2022, 14, 4.	1.7	10
6	Evaluation of viral concentration and extraction methods for SARS-CoV-2 recovery from wastewater using droplet digital and quantitative RT-PCR. <i>Case Studies in Chemical and Environmental Engineering</i> , 2022, 6, 100224.	2.9	9
7	Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3237.	1.7	2
8	KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 2412-2422.	2.1	18
9	Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives. <i>TrAC - Trends in Analytical Chemistry</i> , 2021, 134, 116125.	5.8	88
10	Development and Analytical Validation of a Reverse Transcription Droplet Digital PCR (RT-ddPCR) Assay for PD-L1 Transcripts in Circulating Tumor Cells. <i>Clinical Chemistry</i> , 2021, 67, 642-652.	1.5	16
11	Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382097327.	0.8	14
12	Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients. <i>Scientific Reports</i> , 2021, 11, 2313.	1.6	32
13	Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 780.	1.7	40
14	ESR1 NAPA Assay: Development and Analytical Validation of a Highly Sensitive and Specific Blood-Based Assay for the Detection of ESR1 Mutations in Liquid Biopsies. <i>Cancers</i> , 2021, 13, 556.	1.7	9
15	Androgen Receptor and PIM1 Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 147-156.	1.0	4
16	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. <i>Vaccines</i> , 2021, 9, 207.	2.1	12
17	RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer. <i>Diagnostics</i> , 2021, 11, 513.	1.3	15
18	Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook. <i>Molecular Oncology</i> , 2021, 15, 1683-1700.	2.1	43

#	ARTICLE	IF	CITATIONS
19	Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR. <i>Cancers</i> , 2021, 13, 2736.	1.7	19
20	Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity. <i>Cancers</i> , 2021, 13, 2446.	1.7	5
21	The Effect of Genomic DNA Contamination on the Detection of Circulating Long Non-Coding RNAs: The Paradigm of MALAT1. <i>Diagnostics</i> , 2021, 11, 1160.	1.3	3
22	A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer. <i>Clinical Chemistry</i> , 2021, 67, 1395-1405.	1.5	12
23	What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? â€œ Considerations on pre-analytical aspects by the IFCC workgroup cfDNA. <i>Clinica Chimica Acta</i> , 2021, 520, 168-171.	0.5	20
24	USP44 Promoter Methylation in Plasma Cell-Free DNA in Prostate Cancer. <i>Cancers</i> , 2021, 13, 4607.	1.7	7
25	Association between <i>SOX17</i> , <i>Wif-1</i> and <i>RASSF1A</i> promoter methylation status and response to chemotherapy in patients with metastatic gastric cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e73-e75.	1.4	4
26	Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection. <i>Frontiers in Immunology</i> , 2021, 12, 746203.	2.2	10
27	DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment. <i>Cancers</i> , 2021, 13, 5974.	1.7	9
28	Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows. <i>Clinical Chemistry</i> , 2020, 66, 149-160.	1.5	100
29	The potential of ctDNA analysis in breast cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 54-72.	2.7	22
30	Orexin-A Exerts Equivocal Role in Atherosclerosis Process Depending on the Duration of Exposure: In Vitro Study. <i>Nutrients</i> , 2020, 12, 53.	1.7	2
31	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. <i>Life</i> , 2020, 10, 214.	1.1	31
32	Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000646.	2.0	16
33	PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients. <i>Cancers</i> , 2020, 12, 1188.	1.7	14
34	Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of <i>BRAF</i> V600E mutation in plasma from melanoma patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1799-1807.	1.4	10
35	Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients. <i>Molecular Oncology</i> , 2020, 14, 1001-1015.	2.1	19
36	Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6551.	1.6	34

#	ARTICLE	IF	CITATIONS
37	Liquid biopsy in ovarian cancer. <i>Advances in Clinical Chemistry</i> , 2020, 97, 13-71.	1.8	9
38	<i>PIK3CA</i> hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. <i>Molecular Oncology</i> , 2019, 13, 2515-2530.	2.1	55
39	Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients. <i>Cells</i> , 2019, 8, 652.	1.8	44
40	Nuclease-Assisted Minor Allele Enrichment Using Overlapping Probes-Assisted Amplification-Refractory Mutation System: An Approach for the Improvement of Amplification-Refractory Mutation System-Polymerase Chain Reaction Specificity in Liquid Biopsies. <i>Analytical Chemistry</i> , 2019, 91, 13105-13111.	3.2	29
41	Development and Validation of Multiplex Liquid Bead Array Assay for the Simultaneous Expression of 14 Genes in Circulating Tumor Cells. <i>Analytical Chemistry</i> , 2019, 91, 3443-3451.	3.2	5
42	Multicenter Evaluation of Circulating Plasma MicroRNA Extraction Technologies for the Development of Clinically Feasible Reverse Transcription Quantitative PCR and Next-Generation Sequencing Analytical Work Flows. <i>Clinical Chemistry</i> , 2019, 65, 1132-1140.	1.5	37
43	Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC). <i>Oral Oncology</i> , 2019, 94, 93-100.	0.8	12
44	The Impact of Pre-analytical Factors on the Reliability of miRNA Measurements. <i>Current Pathobiology Reports</i> , 2019, 7, 29-33.	1.6	3
45	HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study. <i>PLoS ONE</i> , 2019, 14, e0215984.	1.1	17
46	Expression pattern of androgen receptors, <i>AR-V7</i> and <i>AR-567es</i> , in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer. <i>Analyst</i> , 2019, 144, 6671-6680.	1.7	21
47	Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers. <i>Oncogene</i> , 2019, 38, 3387-3401.	2.6	109
48	Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes. <i>Translational Research</i> , 2019, 205, 77-91.	2.2	98
49	Liquid biopsies. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 219-232.	1.5	117
50	A pilot plasma-ctDNA ring trial for the Cobas® EGFR Mutation Test in clinical diagnostic laboratories. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, e97-e101.	1.4	6
51	<i>ESR1</i> Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 1500-1510.	3.2	125
52	Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 186-197.	1.4	65
53	Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients. <i>Clinical Chemistry</i> , 2018, 64, 297-306.	1.5	67
54	Circulating Tumor Cells and Circulating Tumor DNA. , 2018, , 235-281.		8

#	ARTICLE	IF	CITATIONS
55	ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 150, 355-360.	0.6	42
56	Evaluation of Preanalytical Conditions and Implementation of Quality Control Steps for Reliable Gene Expression and DNA Methylation Analyses in Liquid Biopsies. <i>Clinical Chemistry</i> , 2018, 64, 1522-1533.	1.5	42
57	Enumeration and Molecular Analysis of CTCs in Metastatic Disease: The Breast Cancer Model. <i>Cancer Drug Discovery and Development</i> , 2017, , 41-65.	0.2	0
58	Exosomes: A Cancer Theranostics Road Map. <i>Public Health Genomics</i> , 2017, 20, 116-125.	0.6	26
59	DNA and Histone Methylation in Lung Cancer. <i>Cancer Drug Discovery and Development</i> , 2017, , 403-436.	0.2	3
60	A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 594-606.	1.1	38
61	Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 1923-1933.	0.6	153
62	<i>RASSF1A</i> promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. <i>Oncotarget</i> , 2017, 8, 21429-21443.	0.8	51
63	Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer. <i>Oncotarget</i> , 2017, 8, 72054-72068.	0.8	36
64	miRNA-21 as a novel therapeutic target in lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2016, 7, 19.	1.3	59
65	Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. <i>Scientific Reports</i> , 2016, 6, 39736.	1.6	96
66	Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients. <i>Clinical Chemistry</i> , 2016, 62, 1002-1011.	1.5	54
67	Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis. <i>Clinica Chimica Acta</i> , 2016, 461, 156-164.	0.5	10
68	Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer. <i>Oncology Letters</i> , 2016, 12, 748-756.	0.8	51
69	MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma. <i>Cancer Medicine</i> , 2016, 5, 656-664.	1.3	50
70	Gene expression profiling and DNA methylation analyses of CTCs. <i>Molecular Oncology</i> , 2016, 10, 431-442.	2.1	45
71	Molecular Assays for the Detection and Molecular Characterization of CTCs. <i>Current Cancer Research</i> , 2016, , 47-74.	0.2	1
72	Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer. <i>Familial Cancer</i> , 2016, 15, 183-191.	0.9	0

#	ARTICLE	IF	CITATIONS
73	SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1385-93.	1.4	66
74	Development and validation of molecular methodologies to assess PALB2 expression in sporadic breast cancer. <i>Clinical Biochemistry</i> , 2016, 49, 253-259.	0.8	5
75	miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 136-144.	1.2	55
76	Low Expression of miR-126 Is a Prognostic Marker for Metastatic Clear Cell Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 2015, 185, 693-703.	1.9	68
77	A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples. <i>Clinica Chimica Acta</i> , 2015, 444, 303-309.	0.5	4
78	An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways. <i>Molecular Oncology</i> , 2015, 9, 1667-1677.	2.1	21
79	Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2015, 778, 46-51.	0.4	68
80	The Role of CTCs as Tumor Biomarkers. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 341-367.	0.8	80
81	miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma. <i>Molecular Therapy</i> , 2015, 23, 1748-1758.	3.7	73
82	Metastasis-related miRNAs: a new way to differentiate patients with higher risk?. <i>Future Oncology</i> , 2015, 11, 365-367.	1.1	2
83	Circulating Tumor Cell Isolation: A Marathon Race Worth Running. <i>Clinical Chemistry</i> , 2014, 60, 287-289.	1.5	18
84	Advancing the education in molecular diagnostics: The IFCC-Initiative "Clinical Molecular Biology Curriculum" (C-CMBC); A ten-year experience. <i>Clinica Chimica Acta</i> , 2014, 436, 5-8.	0.5	2
85	Prognostic Significance of Metastasis-Related MicroRNAs in Early Breast Cancer Patients with a Long Follow-up. <i>Clinical Chemistry</i> , 2014, 60, 197-205.	1.5	84
86	<i>PIK3CA</i> Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5823-5834.	3.2	54
87	Molecular Characterization of Circulating Tumor Cells: Holy Grail for Personalized Cancer Treatment?. <i>Clinical Chemistry</i> , 2014, 60, 1249-1251.	1.5	12
88	Circulating tumor cells as promising novel biomarkers in solid cancers. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 160-171.	2.7	111
89	Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2014, 110, 2054-2062.	2.9	68
90	Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey. <i>Cancer Microenvironment</i> , 2014, 7, 117-131.	3.1	54

#	ARTICLE	IF	CITATIONS
91	Circulating Tumor Cells: A Noninvasive Liquid Biopsy in Cancer. , 2014, , 119-132.		0
92	Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer. Breast Cancer Research, 2013, 15, R20.	2.2	42
93	Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1505-10.	1.4	55
94	Quantification of Circulating miRNAs in Plasma. Journal of Molecular Diagnostics, 2013, 15, 827-834.	1.2	186
95	Lung cancer epigenetics: emerging biomarkers. Biomarkers in Medicine, 2013, 7, 49-58.	0.6	89
96	Breast Cancer Metastasis Suppressor-1 Promoter Methylation in Primary Breast Tumors and Corresponding Circulating Tumor Cells. Molecular Cancer Research, 2013, 11, 1248-1257.	1.5	54
97	CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Clinical Biochemistry, 2013, 46, 235-240.	0.8	70
98	Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer, 2013, 81, 388-396.	0.9	179
99	SOX17 Promoter Methylation in Circulating Tumor Cells and Matched Cell-Free DNA Isolated from Plasma of Patients with Breast Cancer. Clinical Chemistry, 2013, 59, 270-279.	1.5	125
100	Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. British Journal of Cancer, 2013, 108, 2426-2432.	2.9	60
101	Circulating Tumor Cells—New Challenges Ahead. Clinical Chemistry, 2012, 58, 805-807.	1.5	28
102	Development of a multiplexed PCR-coupled liquid bead array assay for vascular endothelial growth factor (VEGF) splice variants. Clinical Biochemistry, 2012, 45, 475-482.	0.8	5
103	A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples. BMC Cancer, 2012, 12, 486.	1.1	14
104	Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment. Cancer and Metastasis Reviews, 2012, 31, 663-671.	2.7	71
105	Molecular Assays for the Detection and Characterization of CTCs. Recent Results in Cancer Research, 2012, 195, 111-123.	1.8	11
106	Circulating Tumor Cells in Breast Cancer: Detection Systems, Molecular Characterization, and Future Challenges. Laboratory Medicine Online, 2012, 2, 59.	0.0	7
107	Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1591-603.	1.4	49
108	Circulating Tumor Cells in Breast Cancer: Detection Systems, Molecular Characterization, and Future Challenges. Clinical Chemistry, 2011, 57, 1242-1255.	1.5	235

#	ARTICLE	IF	CITATIONS
109	Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer, 2011, 11, 422.	1.1	97
110	Circulating Cancer Cells and Their Clinical Applications. Clinical Chemistry, 2011, 57, 1478-1484.	1.5	11
111	DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells. Clinical Chemistry, 2011, 57, 1169-1177.	1.5	145
112	Molecular Characterization of Circulating Tumor Cells in Breast Cancer by a Liquid Bead Array Hybridization Assay. Clinical Chemistry, 2011, 57, 421-430.	1.5	118
113	Circulating tumor cells as emerging tumor biomarkers in breast cancer. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1579-90.	1.4	57
114	Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clinical Biochemistry, 2010, 43, 150-158.	0.8	184
115	Mutation scanning of exon 20 of the BRCA1 gene by high-resolution melting curve analysis. Clinical Biochemistry, 2010, 43, 178-185.	0.8	13
116	PIK3CA Hotspot Mutation Scanning by a Novel and Highly Sensitive High-Resolution Small Amplicon Melting Analysis Method. Journal of Molecular Diagnostics, 2010, 12, 697-704.	1.2	37
117	Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2177-2184.	0.8	246
118	Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. Annals of Oncology, 2009, 20, 1020-1025.	0.6	40
119	Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. Rna, 2009, 15, 1443-1461.	1.6	147
120	Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. International Journal of Cancer, 2009, 125, 2887-2892.	2.3	33
121	Prognostic significance of RASSF1A promoter methylation in operable breast cancer. Clinical Biochemistry, 2009, 42, 970-975.	0.8	29
122	Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) $\hat{1}\pm+\hat{1}^2+$ transcript in estrogen receptor-positive MCF-7 breast cancer cells. Clinical Biochemistry, 2009, 42, 1358-1362.	0.8	29
123	Distinct neutrophil subpopulations phenotype by flow cytometry in myelodysplastic syndromes. Leukemia and Lymphoma, 2009, 50, 401-409.	0.6	12
124	Hypoxia-inducible factor-1 $\hat{1}\pm$ and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Research, 2009, 11, R84.	2.2	111
125	Systemic hypertension augments, whereas insulin-dependent diabetes down-regulates, endothelin A receptor expression in the mammary artery in coronary artery disease patients. Cardiology Journal, 2009, 16, 348-54.	0.5	3
126	Expression profile of total VEGF, VEGF splice variants and VEGF receptors in the myocardium and arterial vasculature of diabetic and non-diabetic patients with coronary artery disease. Clinical Biochemistry, 2008, 41, 82-87.	0.8	20

#	ARTICLE	IF	CITATIONS
127	Asymmetric real-time PCR detection of BRCA1 5382insC mutation by melting curve analysis in the LightCycler. <i>Clinica Chimica Acta</i> , 2008, 390, 141-144.	0.5	16
128	Prognostic Value of Mature MicroRNA-21 and MicroRNA-205 Overexpression in Non-Small Cell Lung Cancer by Quantitative Real-Time RT-PCR. <i>Clinical Chemistry</i> , 2008, 54, 1696-1704.	1.5	415
129	Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 2593-2600.	3.2	220
130	Quantitative Real-Time Reverse Transcription-PCR Study of the Expression of Vascular Endothelial Growth Factor (VEGF) Splice Variants and VEGF Receptors (VEGFR-1 and VEGFR-2) in Non-Small Cell Lung Cancer. <i>Clinical Chemistry</i> , 2007, 53, 1433-1439.	1.5	32
131	Different Prognostic Value of Cytokeratin-19 mRNA-Positive Circulating Tumor Cells According to Estrogen Receptor and HER2 Status in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5194-5202.	0.8	238
132	Real-Time RT-PCR Quantification of Human Telomerase Reverse Transcriptase Splice Variants in Tumor Cell Lines and Non-Small Cell Lung Cancer. <i>Clinical Chemistry</i> , 2007, 53, 53-61.	1.5	39
133	Molecular Detection and Prognostic Value of Circulating Cytokeratin-19 Messenger RNA-Positive and HER2 Messenger RNA-Positive Cells in the Peripheral Blood of Women with Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2007, 7, 883-889.	1.1	48
134	Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. <i>Clinical Biochemistry</i> , 2006, 39, 727-731.	0.8	113
135	HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization. <i>Clinical Biochemistry</i> , 2006, 39, 942-946.	0.8	18
136	Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. <i>Clinical Biochemistry</i> , 2006, 39, 879-887.	0.8	79
137	A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. <i>International Journal of Cancer</i> , 2006, 119, 1654-1659.	2.3	81
138	Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 3756-3762.	0.8	268
139	Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. <i>Clinical Biochemistry</i> , 2005, 38, 50-57.	0.8	21
140	Real-Time Reverse Transcription-PCR Quantification of Vascular Endothelial Growth Factor Splice Variants. <i>Clinical Chemistry</i> , 2005, 51, 1518-1520.	1.5	23
141	Trastuzumab Administration Can Effectively Target Chemotherapy-Resistant Cytokeratin-19 Messenger RNA-Positive Tumor Cells in the Peripheral Blood and Bone Marrow of Patients With Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 8185-8194.	3.2	121
142	Genetic counseling of medullary breast cancer patients. <i>Clinical Genetics</i> , 2004, 65, 343-344.	1.0	4
143	Effect of antineoplastic agents on the expression of human telomerase reverse transcriptase beta plus transcript in MCF-7 cells. <i>Clinical Biochemistry</i> , 2004, 37, 299-304.	0.8	10
144	Atypical Medullary Breast Carcinoma in a Family Carrying the 5382insC BRCA-1 Mutation. <i>Breast Journal</i> , 2003, 9, 260-262.	0.4	6

#	ARTICLE	IF	CITATIONS
145	Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. <i>Annals of Oncology</i> , 2003, 14, 849-855.	0.6	95
146	Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. <i>Clinical Cancer Research</i> , 2003, 9, 5145-51.	3.2	122
147	Development of a highly sensitive RT-PCR luminometric hybridization assay for human telomerase reverse-transcriptase beta-plus transcript. <i>Anticancer Research</i> , 2003, 23, 4821-9.	0.5	2
148	Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. <i>Cancer Letters</i> , 2002, 185, 61-70.	3.2	42
149	Development of a quantitative luminometric hybridization assay for the determination of telomerase activity. <i>Clinical Biochemistry</i> , 2001, 34, 277-284.	0.8	14
150	Quantitative RT-PCR luminometric hybridization assay with an RNA internal standard for cytokeratin-19 mRNA in peripheral blood of patients with breast cancer. <i>Clinical Biochemistry</i> , 2001, 34, 651-659.	0.8	10
151	Determination of tumor necrosis factor- $\hat{\pm}$ (TNF- $\hat{\pm}$) in serum by a highly sensitive enzyme amplified lanthanide luminescence immunoassay. <i>Clinical Biochemistry</i> , 1999, 32, 241-247.	0.8	36
152	Characterization of the BRCA1-like immunoreactivity of human seminal plasma. <i>Urology</i> , 1999, 54, 753-762.	0.5	1
153	Fragment analysis of the p53 gene in ovarian tumors. <i>Clinical Biochemistry</i> , 1998, 31, 551-553.	0.8	1
154	Application of terbium sensitized fluorescence for the determination of fluoroquinolone antibiotics pefloxacin, ciprofloxacin and norfloxacin in serum. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1997, 15, 1839-1844.	1.4	85
155	BRCA1 tumor suppressor gene product shares immunoreactive epitopes with a protein present in seminal plasma. <i>Clinical Biochemistry</i> , 1997, 30, 425-432.	0.8	6
156	Synchronous scanning second derivative spectrofluorimetry for the simultaneous determination of diflunisal and salicylic acid added to serum and urine as ternary complexes with terbium and EDTA. <i>Analytica Chimica Acta</i> , 1996, 320, 107-114.	2.6	29
157	Comparative study of fluorescent ternary terbium complexes. Application in enzyme amplified fluorimetric immunoassay for $\hat{\pm}$ -fetoprotein. <i>Analytica Chimica Acta</i> , 1996, 335, 177-184.	2.6	42
158	Simple, rapid and sensitive spectrofluorimetric determination of diflunisal in serum and urine based on its ternary complex with terbium and EDTA. <i>Analytica Chimica Acta</i> , 1995, 300, 237-241.	2.6	18
159	Second derivative synchronous scanning fluorescence spectrometry as a sensitive detection technique in immunoassays. Application to the determination of $\hat{\pm}$ -fetoprotein. <i>Analytica Chimica Acta</i> , 1994, 290, 159-165.	2.6	24
160	Enzymatic Fluorimetric Determination of Ursodeoxycholic Acid in Urine Using <i>Clostridium Absonum</i> $\hat{\gamma}$ ² -Hydroxysteroid Dehydrogenase. <i>Analytical Letters</i> , 1989, 22, 2265-2280.	1.0	2
161	Determination of ursodeoxycholic acid in serum by a new fluorometric enzymatic method using $\hat{\gamma}$ ² -hydroxysteroid dehydrogenase from <i>Clostridium absonum</i> . <i>Analytical Biochemistry</i> , 1989, 179, 341-346.	1.1	6
162	Enzymic fluorimetric determination of sulphated and non-sulphated primary bile acids in urine using a rapid solvolysis technique. <i>Analyst, The</i> , 1988, 113, 1459.	1.7	6

#	ARTICLE	IF	CITATIONS
163	Determination of kinetic parameters for 3 β -hydroxysteroid dehydrogenase using the five major bile acids and their conjugates as substrates and correlation with their structure and solubility. <i>Analyst</i> , The, 1987, 112, 753-755.	1.7	2